The Interleukin 12 Subunit Beta pipeline drugs market research report outlays comprehensive information on the Interleukin 12 Subunit Beta targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interleukin 12 Subunit Beta pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Immunology, Gastrointestinal, Musculoskeletal Disorders, and Oncology which include the indications Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Crohn’s Disease (Regional Enteritis), Ulcerative Colitis, Psoriatic Arthritis, Axial Spondyloarthritis, Ovarian Cancer, and Endometrial Cancer. It also reviews key players involved in Interleukin 12 Subunit Beta targeted therapeutics development with respective active and dormant or discontinued products.

The Interleukin 12 Subunit Beta pipeline targets constitutes close to 20 molecules. Out of which, approximately 19 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 9, 1, 1, 1, 4, and 2 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.

Interleukin 12 Subunit Beta overview

Interleukin-12 subunit beta (IL-12B) is a protein subunit that is encoded by the IL12B gene in humans. IL-12B is a common subunit of interleukin 12 and interleukin 23. It is secreted as a monomer and interacts with NBR1, which promotes IL-12 secretion. IL-12 is a cytokine that acts on T and natural killer cells and has a broad array of biological activities.

For a complete picture of Interleukin 12 Subunit Beta’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.